Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value
CHICAGO/TOKYO (Reuters) – Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer’s disease drug aducanumab, a major setback in the quest to find…